EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGFβ pathway.
CRISPR
Cas9 nickase
EIF5A2
Epithelial to mesenchymal transition
Lentiviral vector
Orthotopic ovarian cancer mouse model
Ovarian cancer
Journal
Cell & bioscience
ISSN: 2045-3701
Titre abrégé: Cell Biosci
Pays: England
ID NLM: 101561195
Informations de publication
Date de publication:
07 Apr 2021
07 Apr 2021
Historique:
received:
25
09
2020
accepted:
23
03
2021
entrez:
8
4
2021
pubmed:
9
4
2021
medline:
9
4
2021
Statut:
epublish
Résumé
Epithelial to mesenchymal transition (EMT) contributes to tumor metastasis and chemoresistance. Eukaryotic initiation factor 5A2 (EIF5A2) is highly expressed in a variety of human cancers but rarely expressed in normal tissues. While EIF5A2 has oncogenic activity in several cancers and contributes to tumor metastasis, its role in ovarian cancer is unknown. In this study, we investigate whether EIF5A2 contributes to ovarian tumor metastasis by promoting EMT. To investigate the role of EIF5A2, we knocked out (KO) EIF5A2 using lentiviral CRISPR/Cas9 nickase in high invasive SKOV3 and OVCAR8 cells and overexpressed EIF5A2 in low invasive OVCAR3 cells using lentiviral vector. Cell proliferation, migration and invasion was examined in vitro ovarian cancer cells and tumor metastasis was evaluated in vivo using orthotopic ovarian cancer mouse models. Here we report that EIF5A2 is highly expressed in ovarian cancers and associated with patient poor survival. Lentiviral CRISPR/Cas9 nickase vector mediated knockout (KO) of EIF5A2 inhibits epithelial to mesenchymal transition (EMT) in SKOV3 and OVCAR8 ovarian cancer cells that express high levels of EIF5A2. In contrast, overexpression of EIF5A2 promotes EMT in OVCAR3 epithelial adenocarcinoma cells that express relatively low EIF5A2 levels. KO of EIF5A2 in SKOV3 and OVCAR8 cells inhibits ovarian cancer cell migration and invasion, while its overexpression promotes cell migration and invasion in OVCAR3 adenocarcinoma cells. We further demonstrate that EIF5A2 promotes EMT by activating the TGFβ pathway and KO of EIF5A2 inhibits ovarian tumor growth and metastasis in orthotopic ovarian cancer mouse models. Our results indicate that EIF5A2 is an important controller of ovarian tumor growth and metastasis by promoting EMT and activating the TGFβ pathway.
Sections du résumé
BACKGROUND
BACKGROUND
Epithelial to mesenchymal transition (EMT) contributes to tumor metastasis and chemoresistance. Eukaryotic initiation factor 5A2 (EIF5A2) is highly expressed in a variety of human cancers but rarely expressed in normal tissues. While EIF5A2 has oncogenic activity in several cancers and contributes to tumor metastasis, its role in ovarian cancer is unknown. In this study, we investigate whether EIF5A2 contributes to ovarian tumor metastasis by promoting EMT.
METHODS
METHODS
To investigate the role of EIF5A2, we knocked out (KO) EIF5A2 using lentiviral CRISPR/Cas9 nickase in high invasive SKOV3 and OVCAR8 cells and overexpressed EIF5A2 in low invasive OVCAR3 cells using lentiviral vector. Cell proliferation, migration and invasion was examined in vitro ovarian cancer cells and tumor metastasis was evaluated in vivo using orthotopic ovarian cancer mouse models.
RESULTS
RESULTS
Here we report that EIF5A2 is highly expressed in ovarian cancers and associated with patient poor survival. Lentiviral CRISPR/Cas9 nickase vector mediated knockout (KO) of EIF5A2 inhibits epithelial to mesenchymal transition (EMT) in SKOV3 and OVCAR8 ovarian cancer cells that express high levels of EIF5A2. In contrast, overexpression of EIF5A2 promotes EMT in OVCAR3 epithelial adenocarcinoma cells that express relatively low EIF5A2 levels. KO of EIF5A2 in SKOV3 and OVCAR8 cells inhibits ovarian cancer cell migration and invasion, while its overexpression promotes cell migration and invasion in OVCAR3 adenocarcinoma cells. We further demonstrate that EIF5A2 promotes EMT by activating the TGFβ pathway and KO of EIF5A2 inhibits ovarian tumor growth and metastasis in orthotopic ovarian cancer mouse models.
CONCLUSION
CONCLUSIONS
Our results indicate that EIF5A2 is an important controller of ovarian tumor growth and metastasis by promoting EMT and activating the TGFβ pathway.
Identifiants
pubmed: 33827661
doi: 10.1186/s13578-021-00578-5
pii: 10.1186/s13578-021-00578-5
pmc: PMC8025533
doi:
Types de publication
Journal Article
Langues
eng
Pagination
70Subventions
Organisme : NCI NIH HHS
ID : 1R21CA216585-01A1
Pays : United States
Références
Am J Transl Res. 2018 Dec 15;10(12):4269-4279
pubmed: 30662669
Cell Physiol Biochem. 2015;36(6):2494-503
pubmed: 26279450
Int J Cancer. 2011 Jul 1;129(1):143-50
pubmed: 20830705
J Biol Chem. 2015 Jul 24;290(30):18343-60
pubmed: 26037925
Folia Med (Plovdiv). 2019 Jun 1;61(2):296-302
pubmed: 31301662
Cancer. 2017 May 15;123(6):977-984
pubmed: 28263384
J Cancer Res Ther. 2019 Oct-Dec;15(6):1309-1315
pubmed: 31898665
Oncotarget. 2017 Oct 17;8(55):94666-94680
pubmed: 29212257
Hepatology. 2010 Apr;51(4):1255-63
pubmed: 20112425
PLoS One. 2013 Sep 16;8(9):e74250
pubmed: 24066126
J Cell Physiol. 2007 Dec;213(3):581-8
pubmed: 17708542
PLoS One. 2014 Aug 19;9(8):e105331
pubmed: 25137052
Biochem Biophys Res Commun. 2010 Apr 9;394(3):667-72
pubmed: 20226761
Histopathology. 2016 Aug;69(2):276-87
pubmed: 26799253
Int J Hepatol. 2012;2012:760928
pubmed: 23029619
Int J Biol Sci. 2013 Oct 12;9(10):1013-20
pubmed: 24250246
Diagnostics (Basel). 2020 Jun 27;10(7):
pubmed: 32605067
Eur J Biochem. 2003 Nov;270(21):4254-63
pubmed: 14622290
Gut. 2012 Apr;61(4):562-75
pubmed: 21813470
Endocr Relat Cancer. 2016 Mar;23(3):147-59
pubmed: 26647384
Exp Ther Med. 2019 May;17(5):3741-3747
pubmed: 30988760
Oncol Res. 2020 Sep 1;28(4):345-355
pubmed: 32138807
Am J Transl Res. 2017 May 15;9(5):2608-2617
pubmed: 28560008
J Biol Chem. 2015 Dec 11;290(50):29907-19
pubmed: 26483550
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Histol Histopathol. 2020 Jun;35(6):579-587
pubmed: 31745968
Phys Biol. 2019 May 07;16(4):041004
pubmed: 30939460
Amino Acids. 2010 Feb;38(2):491-500
pubmed: 19997760
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Breast Cancer Res. 2011;13(6):226
pubmed: 22078097
Br J Cancer. 2014 Apr 2;110(7):1767-77
pubmed: 24504366
Biochim Biophys Acta. 2015 Jul;1849(7):836-44
pubmed: 25979826
Cancer Res. 2009 Jul 1;69(13):5364-73
pubmed: 19549913
Int J Cancer. 2010 Aug 15;127(4):968-76
pubmed: 19998337
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
PLoS One. 2012;7(12):e52624
pubmed: 23285117
Genomics. 2001 Jan 1;71(1):101-9
pubmed: 11161802
Front Oncol. 2013 Sep 25;3:256
pubmed: 24093089
Front Oncol. 2020 Mar 17;10:319
pubmed: 32257947
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Mol Cancer Ther. 2019 Dec;18(12):2233-2245
pubmed: 31515295
Exp Cell Res. 2013 Oct 15;319(17):2708-17
pubmed: 23958463
APMIS. 2017 Sep;125(9):781-786
pubmed: 28585395
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34
pubmed: 20490631